Pediatrix Medical Group, Inc. (NYSE:MD) Receives $21.00 Average Price Target from Analysts

Shares of Pediatrix Medical Group, Inc. (NYSE:MD) have been given an average rating of “Hold” by the six research firms that are covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating and one has given a buy rating to the company. The average 12-month price target among brokers that have updated their coverage on the stock in the last year is $21.00.

A number of research firms have issued reports on MD. UBS Group increased their price target on Pediatrix Medical Group from $16.50 to $23.00 and gave the stock a “neutral” rating in a report on Wednesday, November 5th. Truist Financial boosted their target price on shares of Pediatrix Medical Group from $17.00 to $24.00 and gave the company a “hold” rating in a research report on Monday, November 10th. Weiss Ratings restated a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Monday, December 29th. Finally, Zacks Research downgraded shares of Pediatrix Medical Group from a “strong-buy” rating to a “hold” rating in a research note on Friday, January 23rd.

Pediatrix Medical Group Stock Up 1.9%

Shares of MD opened at $21.48 on Thursday. The firm has a market cap of $1.84 billion, a P/E ratio of 11.31 and a beta of 0.76. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.83 and a current ratio of 1.83. The firm’s 50-day simple moving average is $21.68 and its 200 day simple moving average is $19.31. Pediatrix Medical Group has a 52 week low of $11.84 and a 52 week high of $24.99.

Insider Buying and Selling

In related news, Director Michael A. Rucker sold 10,478 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $23.00, for a total value of $240,994.00. Following the transaction, the director directly owned 59,101 shares in the company, valued at $1,359,323. This trade represents a 15.06% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Mark S. Ordan sold 23,000 shares of the business’s stock in a transaction on Monday, December 15th. The shares were sold at an average price of $22.41, for a total transaction of $515,430.00. Following the sale, the chief executive officer owned 302,805 shares of the company’s stock, valued at $6,785,860.05. This trade represents a 7.06% decrease in their position. The SEC filing for this sale provides additional information. 0.90% of the stock is currently owned by corporate insiders.

Institutional Trading of Pediatrix Medical Group

Several institutional investors have recently made changes to their positions in the company. Royal Bank of Canada boosted its position in Pediatrix Medical Group by 23.8% during the first quarter. Royal Bank of Canada now owns 22,097 shares of the company’s stock worth $320,000 after purchasing an additional 4,247 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Pediatrix Medical Group by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 51,253 shares of the company’s stock worth $743,000 after buying an additional 2,251 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Pediatrix Medical Group by 4.7% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 268,506 shares of the company’s stock valued at $3,891,000 after buying an additional 12,171 shares in the last quarter. Allianz Asset Management GmbH grew its stake in Pediatrix Medical Group by 159.1% in the 2nd quarter. Allianz Asset Management GmbH now owns 61,412 shares of the company’s stock valued at $881,000 after buying an additional 37,712 shares in the last quarter. Finally, Nordea Investment Management AB raised its holdings in Pediatrix Medical Group by 1.6% during the 2nd quarter. Nordea Investment Management AB now owns 268,219 shares of the company’s stock valued at $3,793,000 after acquiring an additional 4,159 shares during the period. Institutional investors own 97.71% of the company’s stock.

About Pediatrix Medical Group

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.